The comment in Nature Reviews Bioengineering is a key to bridging the gap between early-stage animal studies and real-world clinical treatments for lung diseases. Its first author is Lin Yang together with Otmar Schmid (group leader), Lianyong Han (Institute of Lung Health and Immunity, LHI, Helmholtz Munich) and Chunying Chen from the National Center for Nanoscience and Technology, China.
The problem: nominal dose ≠ effective dose
When new inhaled therapies, especially those using nanotechnology, are tested in animals, researchers often report the total dose “administered.” That is, how much was put in the nebulizer, inhaler, or syringe. But that number doesn’t tell the whole story: much of it can be lost due to inefficiencies like device retention, exhalation, or upper airway deposition.
The article makes a clear point: what truly matters is the dose that actually makes it into the lung tissue - the lung-deposited dose - and even more importantly, where in the lung the drug lands. Without this precision, you can’t accurately compare results across animal models or predict how the drug will behave in humans.
Why this matters for translational research
Consistent Comparisons Across Models: Different species have varying airway structures, breathing patterns, and deposition dynamics. Measuring and reporting the actual lung-deposited dose helps align therapeutic exposure between, say, a mouse and a human.
Improved Prediction of Efficacy and Safety: The portion of drug that reaches the lung influences both effectiveness and side effects. Knowing this “delivered dose” makes it easier to assess therapeutic windows and safety margins accurately.
Better Understanding of Failure or Success: When a treatment fails in a clinical trial, it’s hard to know whether the issue was the drug’s inherent properties or simply poor delivery. Without precise dosimetry, you can’t diagnose the real problem.
This concept, known as precision dosimetry, is increasingly recognized as a critical missing link between preclinical experiments and clinical application.
How research and medicine can improve
The comment doesn’t just issue a warning—it points toward solutions:
- Quantify lung dose directly, wherever possible, rather than relying on nominal dose.
- Use models and methods that estimate not only how much drug is deposited, but also where in the lung it is deposited.
- Enhanced Design of Clinical Trials: If preclinical work reports precise lung exposures, clinical trials can be more strategically designed to mirror those exposures.
- Tailored Therapies: Future treatments could be fine-tuned based on deposition patterns—targeting, for instance, deep alveolar regions versus central airways depending on the disease.
- Transparent Science: Accurate dosimetry fosters trust and reproducibility by giving a clear and honest account of what was tested and how.
These approaches are especially important as the field explores complex therapeutic platforms like nanomedicine, inhaled biologics, and mRNA vaccines delivered to the lungs. It’s a straightforward that could make a real difference in developing therapies for asthma, COPD, lung fibrosis, lung infections, and other chronic lung diseases.
Read the Publication here: www.nature.com/articles/s44222-025-00356-9